Inhibikase Therapeutics Management
Management criteria checks 3/4
Inhibikase Therapeutics' CEO is Milton Werner, appointed in Jun 2010, has a tenure of 14.42 years. total yearly compensation is $811.43K, comprised of 62.9% salary and 37.1% bonuses, including company stock and options. directly owns 1.32% of the company’s shares, worth €1.96M. The average tenure of the management team and the board of directors is 10.3 years and 3.9 years respectively.
Key information
Milton Werner
Chief executive officer
US$811.4k
Total compensation
| CEO salary percentage | 62.9% |
| CEO tenure | 14.4yrs |
| CEO ownership | 1.3% |
| Management average tenure | 10.3yrs |
| Board average tenure | 3.9yrs |
Recent management updates
No updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$20m |
| Jun 30 2024 | n/a | n/a | -US$18m |
| Mar 31 2024 | n/a | n/a | -US$19m |
| Dec 31 2023 | US$811k | US$510k | -US$19m |
| Sep 30 2023 | n/a | n/a | -US$19m |
| Jun 30 2023 | n/a | n/a | -US$19m |
| Mar 31 2023 | n/a | n/a | -US$18m |
| Dec 31 2022 | US$744k | US$501k | -US$18m |
| Sep 30 2022 | n/a | n/a | -US$19m |
| Jun 30 2022 | n/a | n/a | -US$19m |
| Mar 31 2022 | n/a | n/a | -US$17m |
| Dec 31 2021 | US$611k | US$455k | -US$15m |
| Sep 30 2021 | n/a | n/a | -US$11m |
| Jun 30 2021 | n/a | n/a | -US$7m |
| Mar 31 2021 | n/a | n/a | -US$5m |
| Dec 31 2020 | US$961k | US$293k | -US$3m |
| Sep 30 2020 | n/a | n/a | -US$2m |
| Jun 30 2020 | n/a | n/a | -US$3m |
| Mar 31 2020 | n/a | n/a | -US$5m |
| Dec 31 2019 | US$385k | US$293k | -US$6m |
| Sep 30 2019 | n/a | n/a | -US$7m |
| Mar 31 2019 | n/a | n/a | -US$4m |
| Dec 31 2018 | US$535k | US$452k | -US$2m |
Compensation vs Market: Milton's total compensation ($USD811.43K) is about average for companies of similar size in the German market ($USD782.05K).
Compensation vs Earnings: Milton's compensation has increased whilst the company is unprofitable.
CEO
Milton Werner (60 yo)
14.4yrs
Tenure
US$811,429
Compensation
Dr. Milton H. Werner, Ph D., serves as the Chief Executive Officer and President at Inhibikase Therapeutics, Inc. since June 2010. Prior to founding Inhibikase, From May 2007 until August 2008, Dr. Werner...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 14.4yrs | US$811.43k | 1.32% € 2.0m | |
| Chief Financial Officer | less than a year | no data | 0% € 0 | |
| Head of Chemistry | 10.3yrs | no data | no data | |
| Controller | no data | no data | no data |
10.3yrs
Average Tenure
Experienced Management: IQT0's management team is seasoned and experienced (10.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 14.4yrs | US$811.43k | 1.32% € 2.0m | |
| Independent Director | 3.9yrs | US$74.85k | 0% € 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.9yrs | US$65.85k | 0% € 0 | |
| Chairman | less than a year | no data | 2.17% € 3.2m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | less than a year | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
3.9yrs
Average Tenure
65.5yo
Average Age
Experienced Board: IQT0's board of directors are considered experienced (3.9 years average tenure).